Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 21, 2007

Oncolys and Tacere Forge Alliance to Develop RNAi HCV Drug

  • Oncolys BioPharma signed an agreement to develop Tacere Therapeutics’ drug candidate for the treatment of HCV. TT-033 is an RNAi-based product.

    Under this agreement, Oncolys has been granted an option to acquire the Asian rights for TT-033. “HCV continues to be a significant public health crisis in Japan, China, and Korea, and we look forward to Oncolys' expert guidance along the regulatory and marketing path in Asia," remarks Sara M. Hall, Tacere’s president and CEO.

    Tacere reports that it will begin IND-enabling studies on TT-033 shortly and plans to enter Phase I trials in late 2008.



Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »